Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zafirlukast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| zafirlukast | EXPERIMENTAL | Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited |
| Accolate | ACTIVE_COMPARATOR | ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals |
| Name | Type | Description |
|---|---|---|
| Zafirlukast | DRUG | Zafirlukast tablets 20 mg |
Inclusion Criteria: 1. The subjects should be healthy human between 18 and 45 years. 2. The subjects should be screened within 21 days prior to the administration of first dose of the study drug. 3. The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter. 4. The subjects...
Zafirlukast is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated for its pharmacokinetic properties, specifically in a bioequivalence study.
Zafirlukast is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical trials to evaluate the drug's bioequivalence.
Zafirlukast is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The current development stage involves early clinical trials in healthy subjects.
Zafirlukast is being studied in a completed Phase 1 clinical trial with the identifier NCT01283061. This trial was a bioequivalence study of Zafirlukast tablets 20 mg conducted under fasting conditions in healthy volunteers in India.
Zafirlukast is the drug name used in the clinical trial. No alternative names have been reported for this drug in the available information. It is being studied as a tablet formulation.